The Food and Drug Administration yesterday authorized for emergency use a new drug to treat hospitalized patients receiving systemic corticosteroids who require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation. Actemra (tocilizumab) reduced the risk of death, ventilator use and time in the hospital for patients who received the drug in clinical trials. 

“Although vaccines have been successful in decreasing the number of patients with COVID-19 who require hospitalization, providing additional therapies for those who do become hospitalized is an important step in combating this pandemic,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research.

In other news, FDA is accepting comments through Aug. 24 on draft guidance encouraging clinical trials for cancer therapies to expand eligibility to patients with incurable cancers who have not previously received existing treatment options for their cancer. 
 

Related News Articles

Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…